URMC / Research / Clinical Trials / Study Details

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Research Question:
Does the drug erdafitinib treat patients with solid tumors, non-Hodgkin lymphoma or histiocytic disorders?

Basic Study Information

Purpose:
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher: Angela Girvin

Study Contact Information

Study Coordinator: Site Public Contact
Phone: (585) 275-5830

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Wilmot Clinical Trials